EVFM — Evofem Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro CapValue Trap
- $3.46m
- $73.24m
- $8.24m
Annual income statement for Evofem Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.446 | 8.24 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.078 | 4.19 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 10 | 77.8 | 52.7 | 104 | 175 |
| Operating Profit | -10 | -77.8 | -52.7 | -104 | -167 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.99 | -126 | -80 | -142 | -205 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.99 | -126 | -80 | -142 | -205 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -9.99 | -126 | -80 | -142 | -205 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.99 | -126 | -80 | -142 | -206 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -65 | -86.1 | -29.8 | -31.8 | -23.6 |